AVDL - Avadel Pharmaceuticals GAAP EPS of -$0.83 misses by $0.45 revenue of $1.5M beats by $0.77M
2023-08-09 07:08:37 ET
- Avadel Pharmaceuticals press release ( NASDAQ: AVDL ): Q2 GAAP EPS of -$0.83 misses by $0.45 .
- Cash, cash equivalents and marketable securities were $160.5 million as of June 30, 2023. In May 2023, the Company exercised its option to exchange $106.3 million in senior convertible notes due 2027 for approximately 12.3 million American Depositary Shares and cash payment of $1.5 million for accrued interest.
- Revenue of $1.5M beats by $0.77M .
For further details see:
Avadel Pharmaceuticals GAAP EPS of -$0.83 misses by $0.45, revenue of $1.5M beats by $0.77M